ADURAduro Clean Technologies Inc.
This is the year ADUR has to prove it’s not just another greenwashing story — it’s the year it either becomes a real player in the industrial pollution controls space or gets swallowed by the next wave of tech-driven disruptors. The next catalyst is the Pilot Plant Demonstration on 2026-10-28, which anchors the price at $18.00 and sets up a bull target of $15.50 (lean n/a) and a bear fallback of n/a. If the pilot goes as planned, the stock could test the $15.50 level, but if it fails, the whole narrative could collapse. Either way, this is the first real test of whether ADUR can deliver on its promise of scalable, cost-effective pollution control tech.
The schedule
- Wed28Oct
- Tue12Jan
- Thu14Jan
- Thu8Apr
- Tue13Apr
- Tue13Jul
- Tue12Oct
Past
- Thu27Aug
Actual outcome: Bull · $11.97 at outcome
Aduro reported Q3 FY2026 EPS of -$0.049, perfectly meeting analyst estimates, while highlighting key progress in its NGP Pilot Plant operations and FOAK development at Chemelot. The in-line earnings, combined with positive updates on commercialization partnerships and the subsequent expansion of its Hydrochemolytic Technology to paraffinic crude oils, reinforced confidence in the company's growth trajectory and drove the stock well past the bull target.
Aduro reported Q3 FY2026 EPS of -$0.049, perfectly meeting analyst estimates, while highlighting key progress in its NGP Pilot Plant operations and FOAK development at Chemelot. The in-line earnings, combined with positive updates on commercialization partnerships and the subsequent expansion of its Hydrochemolytic Technology to paraffinic crude oils, reinforced confidence in the company's growth trajectory and drove the stock well past the bull target.
- Tue14Jul
Actual outcome: Bear · $13.40 at outcome
Aduro met EPS estimates exactly, but shares fell 16.4% following the Q2 earnings release. While the company announced the completion of Phase 1 feedstock mapping with ECOCE, the lack of broader commercialization updates or a clear capital deployment schedule for its Hydrochemolytic technology disappointed investors, driving the stock down toward the bear floor.
Aduro enters Q2 earnings with a substantially fortified balance sheet, reporting over $39.4M in cash. The focus shifts entirely from liquidity concerns to execution metrics. A bullish outcome to $17.50 requires management to confirm the deployment schedule for this capital toward scaling its Hydrochemolytic technology, while a failure to outline clear commercialization steps could see shares retreat to the 200-day SMA near $12.80.